Trans-Geranylgeraniol (GGOH): A Comprehensive Reference
1. Identity, Nomenclature, and Chemical Character
Trans-geranylgeraniol — commonly abbreviated GGOH or GG — is a naturally occurring diterpene alcohol belonging to the broader class of isoprenoid (terpenoid) compounds.
Its IUPAC name is (E,E,E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-ol; it is also listed under the names All-trans-Geranylgeraniol and simply Geranylgeraniol. Its CAS Registry Number is 24034-73-9, its molecular formula is C20H34O, and its molecular weight is 290.48 g/mol.
Structurally, geranylgeraniol is a diterpene alcohol composed of four isoprene units, giving it twenty carbon atoms, which places it within the larger family of isoprenoids. The "trans" (all-E) designation refers to the geometry at each of the three internal double bonds; the fully extended all-trans configuration is the biologically predominant and commercially employed form.
All-trans-geranylgeraniol (GGO) is a 20-carbon, cell-permeable isoprenoid molecule, which may be phosphorylated within cells to yield geranylgeranyl pyrophosphate (GGPP).
The compound is synthesized naturally within the human body via the mevalonate pathway.
Isoprenoids are the output of the polymerization of five-carbon, branched isoprenic chains derived from isopentenyl pyrophosphate (IPP) and its isomer, dimethylallyl pyrophosphate (DMAPP); isoprene units are consecutively condensed to form longer structures such as farnesyl and geranylgeranyl pyrophosphate (FPP and GGPP, respectively), necessary for the biosynthesis of several metabolites.
Free polyprenols such as farnesol (FOH) and geranylgeraniol (GGOH) can be incorporated into prenylated proteins, ubiquinone, cholesterol, and dolichols.
1.1 Common Synonyms and Abbreviations
- All-trans-Geranylgeraniol
- GGOH (most common scientific abbreviation)
- GG (common supplemental and clinical abbreviation)
- GGO (used in some older literature)
- trans-GG or (E,E,E)-Geranylgeraniol
1.2 Natural Sources
Isoprenoids play widely differing roles in various physiological processes in animals and plants; geranylgeraniol (GGOH) is an isoprenoid found in plants and is an important metabolic derivative in the isoprenoid/cholesterol synthesis pathway.
Geranylgeraniol is particularly abundant in annatto (Bixa orellana).
GGOH is the major oily constituent of annatto seeds (constituting approximately 1% of dry seeds) and annatto food color extracts.
Annatto is a crude pigment extract derived from the Bixa orellana (Achiote) shrub, which is native to tropical America, and is used as a color additive in human food, pharmaceuticals, and cosmetics.
GGOH also occurs naturally in certain foods such as flax, sunflower, and olive oils, as well as select medicinal herbs, but the majority in the human body is synthesized endogenously. GG is an essential building block for the production of CoQ10, vitamin K2, and testosterone, as well as for protein synthesis.
Other dietary sources include oils from flaxseed, sunflower, and olives, where it functions as a component of the plant's natural defense and metabolic systems.
One commercially developed nutraceutical formulation, Ormona®, uses annatto oil granules from Bixa orellana (42.5% of the formulation); the annatto oil in this preparation contains 10% tocotrienols (mainly the δ isomer) and 28% geranylgeraniol.
1.3 Common Forms and Preparations
GGOH supplements are derived from natural sources, such as the annatto plant, and are often formulated as softgels due to the compound's fat-soluble nature. Commercial preparations include liquid-filled softgel capsules and liquid capsules, sometimes combined with tocotrienol-form vitamin E extracts also derived from annatto. The compound is characteristically oily and hydrophobic, necessitating fat-based delivery systems to facilitate absorption.
2. Traditional and Historical Use
Geranylgeraniol is a naturally occurring diterpenoid alcohol found in several plants and essential oils, including ginger, turmeric, and lemongrass; historically, while pure geranylgeraniol was not isolated until recent decades, its plant sources have long been used in traditional medicine.
For centuries, remedies leveraging ginger and turmeric have been integral to Ayurvedic and Traditional Chinese Medicine for their anti-inflammatory, antioxidant, and circulatory benefits. However, it is important to note that these traditions attributed benefits to the whole plants or their complex extracts; geranylgeraniol as an isolated compound was not identified, named, or employed in historical medicine. The compound was not isolated in pure form until modern chemical analysis became available.
Annatto, one of the most abundant natural sources of geranylgeraniol, is a native Brazilian plant that has long been used in folk medicine to treat a large number of illnesses. In traditional Amazonian and Caribbean cultures, annatto seeds (known regionally as achiote or urucum) were employed as a food colorant, a body paint, a sunscreen, and in folk preparations for fever, stomach disorders, skin ailments, and to support sexual health — uses rooted in the whole seed or its resinous extract, not in any identified constituent. The identification of geranylgeraniol as a specific and abundant isoprenoid within annatto is a product of 20th- and 21st-century phytochemical analysis.
3. Key Constituents, Biochemistry, and Mechanisms of Action
3.1 Position in the Mevalonate Pathway
The rate-limiting step of the mevalonate pathway is the conversion of HMG-CoA to mevalonate, catalyzed by the enzyme HMG-CoA reductase.
Mevalonate is an intermediate in the synthesis of cholesterol (essential for membrane integrity), dolichol (required for glycoprotein synthesis), polyisoprenoid side chains of heme A and ubiquinone (involved in oxidative respiration), and isopentyladenine (present in some tRNAs); furthermore, mevalonate is also a precursor of the isoprenoids FPP and GGPP.
Geranylgeranyl pyrophosphate synthase (GGPPS) converts farnesyl pyrophosphate (FPP) to geranylgeranyl pyrophosphate (GGPP) in the mevalonate pathway.
All-trans-geranylgeraniol is a cell-permeable isoprenoid molecule which may be phosphorylated within cells to yield GGPP. This cell-permeability is a critical pharmacological property: because GGOH is the unphosphorylated (alcohol) form, it can cross cell membranes and be converted intracellularly to the active GGPP, effectively bypassing the need for de novo synthesis through upstream enzymatic steps.
3.2 Protein Prenylation
Both FPP and GGPP can be transferred to proteins containing the CaaX motif under the action of farnesyltransferase or geranylgeranyl transferase (GGTase); this phenomenon is called protein prenylation (farnesylation and geranylgeranylation).
Prenylated proteins can be targeted to the membrane to perform their biological functions; the gamma subunits of some small G proteins, such as Ras, Rab, and RhoA superfamily proteins, undergo prenylation after protein translation, permitting their localization at the membrane and their functional activity.
These isoprenoids are used for the post-translational modification of proteins, including Ras (farnesylation) and the Rho family members Rac-1, RhoA, and Cdc42 (geranylgeranylation); farnesyltransferase and GGTase transfer farnesyl and geranylgeranyl moieties from FPP and GGPP, respectively, to the thiol group of conserved cysteine residues at or near the C-terminus of target proteins. Loss of GGPP — such as occurs during statin or bisphosphonate therapy — therefore disrupts the membrane anchoring of these critical regulatory proteins.
3.3 Precursor to CoQ10 (Ubiquinone) and Vitamin K2
Geranylgeraniol is a naturally occurring isoprenoid alcohol found in several plants and is a key intermediate in the biosynthesis of vital molecules such as coenzyme Q10 and vitamin K2.
GG is an obligatory substrate for CoQ10 synthesis, an endogenous nutrient critical for skeletal muscle protein synthesis. Vitamin K2 (specifically the MK-4 subtype) is produced from geranylgeraniol via a dedicated enzymatic pathway; the side chain of menaquinone-4 is structurally identical to the carbon chain of GGOH, and GGOH serves as the direct side-chain precursor in its biosynthesis.
3.4 Anti-Inflammatory Mechanisms
Geranylgeraniol (GGOH), a natural C20 isoprenoid found in plants and structurally similar to the side chain of menaquinone-4, exhibited anti-inflammatory actions in human peripheral blood mononuclear cells (PBMC), as well as in a mouse model of alendronate-induced inflammation.
GGOH dose-dependently suppressed the LPS-induced increase in the mRNA levels of Il-1β, Tnf-α, Il-6, and Cox-2; furthermore, GGOH inhibited the phosphorylation of TAK1, IKKα/β, and NF-κB p65 proteins as well as NF-κB nuclear translocation induced by LPS, while maintaining IκBα expression. GGOH, similar to menaquinone-4, could alleviate LPS-induced microglial inflammation by targeting the NF-κB signaling pathway.
GGOH also maintained endotoxin tolerance in murine peritoneal macrophages and suppressed the expression of LPS-induced inflammatory cytokines in bisphosphonate-treated RAW264.7 cells; in addition to other isoprenoids, GGOH has been shown to inhibit NFκB activation.
3.5 Relationship to the Mevalonate Pathway in Disease Contexts
Farnesol (FOH) and GGOH have been shown to block the effects of isoprenoid biosynthesis inhibitors such as fosmidomycin, bisphosphonates, or statins in several organisms. This "rescue" function underpins much of the current research interest in GGOH as a dietary supplement and potential adjunct therapy.
Earlier studies focused on GGOH's ability to improve the side effects of bisphosphonate therapy by regulating the mevalonate pathway; more recently, the mevalonate pathway-independent effects of GGOH have been described, including anti-inflammatory, anti-tumorigenic, and neuroprotective activities.
4. Scientific Evidence by Area of Use
4.1 Statin-Associated Muscle Symptoms (SAMS)
Background and Rationale
Myopathy is the most common side effect of statins, but it has not been addressed effectively; statins act by suppressing the mevalonate pathway, which in turn affects the downstream synthesis of isoprenoids required for normal physiological functions; CoQ10 and geranylgeraniol (GG) syntheses are both reduced by statin use.
CoQ10 supplementation has not been shown to reverse SAMS; GG is an obligatory substrate for CoQ10 synthesis, an endogenous nutrient critical for skeletal muscle protein synthesis. This mechanistic distinction is significant: rather than supplementing a downstream product (CoQ10), GGOH acts more proximally in the pathway.
In Vitro and Ex Vivo Evidence
Mevastatin reduced the synthesis of cholesterol, geranylgeranyl pyrophosphate, and ubiquinone, mitochondrial electron transport, activity of RhoA and Rac, and cell proliferation, accompanied by increased cell death; geranylgeraniol, a cell-permeable analogue of GGPP, reversed all these effects of mevastatin without affecting its ability to reduce cholesterol synthesis. Notably, geranylgeraniol was more effective than the addition of exogenous ubiquinone, which rescued mitochondrial respiratory activity and reversed mevastatin cytotoxicity but did not alter the decrease in cell proliferation.
The administration of geranylgeranyl pyrophosphate (GGPP) or its precursor geranylgeraniol (GGOH) has been shown by several in vitro studies to be capable of abrogating statin-induced myotoxicity; findings demonstrated that while GGOH fully reverted the statin-mediated cell viability in proliferating myoblasts, water-soluble cholesterol exclusively rescued membrane-disruption toxicity; statins caused loss of prenylated RAP1, whereas the GGOH-dependent positive effect was accompanied by loss of non-prenylated RAP1.
In an ex vivo human study, statin caused the induction of atrogin-1 by ≥ 400%, an indication of muscle damage and muscle atrophy; these studies showed GG reduced atrogin-1 to reverse muscle atrophy.
The cytoprotective effect of GGOH in skeletal muscle harmed by statin-associated myopathy was investigated using the C2C12 cell line as an in vitro model of muscle cells; GGOH via autophagy induction was assumed to prevent skeletal muscle viability impaired by statins; autophagy appeared important for the differentiation of muscle cells but did not participate in the observed GGOH cytoprotective effects; ATR- and SIM-dependent loss in cell viability was reversed by GGOH co-treatment, although GGOH did not reverse the ATR-induced drop in cytochrome c oxidase protein expression level.
Animal (Preclinical) Evidence
A study aimed to evaluate the ability of GGOH to prevent SAMS in rodents; female Wistar rats (12 weeks of age) were randomized to one of four treatment groups: control, control with GGOH, simvastatin, or simvastatin with GGOH; ex vivo assessment of force production was conducted in skeletal muscles of varying fiber composition; ex vivo left ventricular performance and blood vessel function was also assessed to determine if the administration of GGOH caused adverse changes; statin administration was associated with reduced force production in fast-twitch glycolytic muscle, but co-administration with GGOH completely abrogated this effect; gastrocnemius muscles isolated from the simvastatin group exhibited a significant decline in muscle force production, an effect which GGOH treatment completely abrogated.
Vascular relaxation was also maintained following treatment with GGOH; the findings of this study demonstrate that GGOH can prevent statin-induced skeletal muscle fatigue in rodents without causing adverse changes in cardiovascular function.
Human / Clinical Evidence
Multiple studies showed GG supplementation is effective in reversing SAMS; an opinion paper published in Frontiers in Physiology (2023) proposes employing GG to prevent SAMS in pleiotropic statin use, including usage in the post-COVID-19 pandemic era. However, this paper is explicitly an opinion piece and not a controlled clinical trial.
A 2023 paper published in Frontiers in Physiology discusses the potential role of geranylgeraniol in managing statin-associated muscle symptoms; this preclinical data is currently being put to the test in human trials; Texas Tech University Health Sciences Center is conducting an ongoing 12-week, randomized, placebo-controlled clinical trial testing annatto-derived GG on adults experiencing new-onset statin muscle pain. This trial had not yet published results at the time of the available literature.
Studies have shown that GGOH supplementation can be effective in reversing myopathy in animal models, and clinical trials are currently investigating its ability to improve muscle outcomes in human statin users.
Evidence strength assessment: The mechanistic and preclinical evidence for GGOH in SAMS is substantial and internally consistent across multiple independent laboratories. However, at the time of publication, controlled human clinical trial results demonstrating efficacy on muscle outcomes in statin users had not yet been published. Evidence remains primarily preclinical (in vitro, ex vivo, and animal models), with human trials ongoing. No conclusions about clinical efficacy can yet be drawn from controlled human data.
4.2 Bisphosphonate-Related Osteonecrosis of the Jaw (MRONJ/BRONJ) and Bone Cell Biology
Mechanism
Nitrogen-containing bisphosphonates (N-BPs) act by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway; inhibition of farnesyl diphosphate synthase prevents the synthesis of farnesyl diphosphate and its derivative, geranylgeranyl diphosphate (GGPP); at the molecular level, this results in the loss of isoprenoid intermediates, altering protein prenylation which is required for the posttranslational maturation of small GTP-binding proteins, including those in the Ras, Rho, Rab, Arf, and Ran families.
Medication-related osteonecrosis of the jaw (MRONJ) is a morbid condition including exposed, infected bone and mandibular fractures in osteoporotic individuals and metastatic cancer patients treated with nitrogen-containing bisphosphonates (NBPs); NBPs inhibit farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, depriving osteoclasts and other bone cells of small GTPases necessary for their function and survival.
In Vitro Evidence
GGOH is an intermediate product in the mevalonate pathway having positive effects on different cell types treated with bisphosphonates by salvaging protein prenylation, improving cell viability and proliferation in tissue regeneration, thus overcoming N-BP-induced apoptosis.
Although high concentrations of zoledronate significantly decreased cell viability in bone cells, GGOH reversed this action of ZA (while at very high concentrations of GGOH, severe reduction in cell viability was also observed); Rap1A, a member of the GTPases family, was expressed in negative controls but was absent in cells treated with high concentrations of ZA; the addition of GGOH increased the expression of Rap1A up to a certain limit; the experiments proved that ZA acts directly on the mevalonate pathway and protein prenylation, and that GGOH could be applied as a future local therapy to MRONJ.
Analysis of the influence of geranyl-geraniol addition on four bisphosphonate derivatives (clodronate, pamidronate, ibandronate, and zoledronate) regarding their influence on cell viability and migration ability of bone metabolism and endothelial cells in vitro showed that all bisphosphonates depressed the migration ability of dermal fibroblasts, endothelial progenitor cells, and human osteoblasts.
Alendronate (ALN), a nitrogen-containing bisphosphonate, acts as an inhibitor of enzymes in the mevalonate pathway, reducing osteoblast viability and mineralization; GGOH is a substrate in the mevalonate pathway and mediates protein prenylation; ALN decreased mineralization, and in the presence of ALN, GGOH addition at the first week of culture increased mineralization compared with addition at other time points.
Animal Evidence
Release of GGOH from bone cement increased osteoclast survival/metabolic activity and promoted resorption of the calcified substrate; in vivo released GGOH limited the effects of the bisphosphonate and promoted healing.
Geranylgeraniol (GGOH), incorporated into a bone cement pellet, promotes osteoclast function and healing in a model of medication-related osteonecrosis of the jaw.
Several considerations for using GGOH in the clinical management of BRONJ have been highlighted; as a conclusion, GGOH is a promising topical agent to manage BRONJ, pending more research on an effective delivery system and validation from a clinical trial.
Evidence strength assessment: There is a substantial and growing body of in vitro and animal evidence supporting the role of GGOH in counteracting bisphosphonate-induced bone cell dysfunction. No controlled human clinical trials for GGOH in MRONJ had been published at the time of the available literature. Evidence is currently preclinical only.
4.3 Bone Microarchitecture, Glucose Homeostasis, and Metabolic Health
Animal Evidence
The purpose of a published study was to test the hypothesis that GGOH supplementation would improve glucose homeostasis and benefit bone microstructure in obese mice through suppression of inflammation and modification of gut microbiota composition; thirty-six male C57BL/6J mice were divided into three groups: a low-fat diet, a high-fat diet (HFD), and an HFD supplemented with 800 mg GGOH/kg diet for 14 weeks; glucose and insulin tolerance tests were measured at baseline and end of study.
Relative to the HFD group, the GGOH-supplemented group improved glucose tolerance and insulin sensitivity; reduced production of pro-inflammatory adipokines; increased serum procollagen I intact N-terminal propeptide (a bone formation marker) concentrations while decreasing serum collagen type 1 cross-linked C-telopeptide (a bone resorption marker) levels; and increased stiffness at both femur and lumbar vertebra-4 and cortical thickness at femoral midshaft; the GGOH group also had an increased abundance of Butyricicoccus pullicaecorum and decreased Dorea longicatena in the cecal microbiome; collectively, GGOH improves glucose homeostasis and bone microstructure in obese mice, probably via suppression of pro-inflammation and modification of microbiome composition.
A further study tested the hypothesis that the combination of geranylgeraniol (GGOH) and green tea polyphenols (GTPs) could alleviate high-fat-diet-induced muscle atrophy and alter gut microbiome composition; male C57BL/6J mice fed an HFD were assigned to four groups in a 2 × 2 factorial design (400 mg GGOH/kg diet vs. no GGOH; 0.5% w/v GTPs in water vs. no GTPs) for 14 weeks; the group that consumed a combination of GGOH and GTPs had significantly decreased body and fat mass but increased skeletal muscle mass normalized by body weight and cross-sectional area.
Evidence strength assessment: Evidence in this area is entirely from rodent models. No human clinical trials on GGOH for glucose homeostasis, obesity, or bone microarchitecture have been published. Results are hypothesis-generating for future human research.
4.4 Testosterone and Steroidogenesis
Preclinical Evidence
Earlier studies focused on GGOH's ability to improve the side effects of bisphosphonate therapy by regulating the mevalonate pathway; more recently, mevalonate pathway-independent effects of GGOH have been described, including anti-inflammatory, anti-tumorigenic, and neuroprotective activities; it is noteworthy that GGOH regulates the steroidogenesis pathway in testis-derived I-10 tumor cells.
GGOH enhanced testosterone and progesterone (its precursor) levels in I-10 cells by activating adenylate cyclase via cAMP/PKA signaling, without altering phosphodiesterase activity.
Registered Human Trials
An 18-week crossover, placebo-controlled pilot study of GG supplementation is registered, with the primary purpose of investigating the effects of geranylgeraniol (GG) supplementation on testosterone levels in middle-aged (40 to 65 years) healthy men and women; the research team hypothesizes that GG supplementation will enhance testosterone levels and improve self-reported health outcomes; all study outcomes will be measured at baseline and at the conclusion of the first 8-week period; this will be followed by a 2-week washout period, with study procedures repeated for a second 8-week block.
All participants are to receive either a placebo (300 mg medium chain triglycerides/daily) or geranylgeraniol supplementation (300 mg GG/daily).
Evidence strength assessment: The testosterone evidence is currently limited to a single cell-line study (testis-derived tumor cells). Human trials are registered (ClinicalTrials.gov NCT06747624) but results had not been published at the time of available literature. This area remains speculative for human application.
4.5 Neuroinflammation and Neuroprotection
Persistent inflammatory reactions in microglial cells are strongly associated with neurodegenerative pathogenesis; geranylgeraniol (GGOH), a plant-derived isoprenoid, has been found to improve inflammatory conditions in several animal models; its chemical structure is similar to that of the side chain of menaquinone-4, which is a vitamin K2 sub-type that suppresses inflammation in mouse-derived microglial cells.
GGOH dose-dependently suppressed the LPS-induced increase in the mRNA levels of Il-1β, Tnf-α, Il-6, and Cox-2; GGOH inhibited the phosphorylation of TAK1, IKKα/β, and NF-κB p65 proteins as well as NF-κB nuclear translocation induced by LPS while maintaining IκBα expression; GGOH, similar to menaquinone-4, could alleviate LPS-induced microglial inflammation by targeting the NF-κB signaling pathway.
Geranylgeraniol shows neuroprotective and osteoprotective capacity; one study examined GG's effects on pain-associated behaviors, glucose homeostasis, gut microbiota, mitochondrial homeostasis, and bone microstructure in diabetic neuropathy rats; GG increased alpha-diversity in the gut microbiome without changing microbial abundance; GG did not reverse diabetic neuropathy-induced gut dysbiosis but increased colonic claudin-3 (tight junction), MFN1 (mitochondria fusion), and TFAM (mitochondria biogenesis), while reducing FIS1 (mitochondria fission), GFAP (glial activation), and TNFα (inflammation).
Evidence strength assessment: Neuroprotective and anti-neuroinflammatory effects have been demonstrated in cell-line and rodent models. No human clinical data exist in this area.
4.6 Mevalonate Kinase Deficiency (HIDS) — Rare Disease Research
Mevalonate kinase (MVK) deficiency, a rare autosomal recessive disease, significantly impacts metabolism and immunity, leading to mevalonic aciduria in severe cases and hyper-IgD syndrome (HIDS) in partial deficiency; these conditions arise due to disruptions in the mevalonate pathway, which is an essential metabolic pathway responsible for the synthesis of non-sterol isoprenoids and other molecules; the resulting metabolic blockade triggers autoinflammatory responses, primarily due to deficient isoprenoid intermediates such as GGPP; a first-reported pilot study evaluated the safety and efficacy of dietary geranylgeraniol supplementation in three patients with HIDS.
Proteomic analysis revealed that GG supplementation can reverse some of the features of HIDS-specific plasma protein signature, highlighting its potential to modulate inflammation and protein prenylation. This was a small pilot study (n = 3), published as a preprint in medRxiv in 2024. The findings are very preliminary and require replication in larger controlled studies.
Evidence strength assessment: Extremely limited (three patients); findings are preliminary and hypothesis-generating only.
4.7 Anti-Cancer / Anti-Tumorigenic Considerations
Geranylgeraniol (GGO) induces apoptosis in human leukemia HL60 cells, and this process is linked to intracellular acidification; the induction of apoptosis by GGO is dependent on early changes in intracellular calcium levels and a decrease in pH.
Geranylgeraniol effectively suppresses the growth of human prostate carcinoma cells, with an IC50 value of 80 ± 18 µmol/L after 72 hours, indicating its potential as a therapeutic agent.
An important cautionary note exists in the oncology space:
Pitavastatin-induced apoptosis was blocked by geranylgeraniol and mevalonate, confirming that pitavastatin causes cell death through inhibition of HMGCR; solvent extracts of human and mouse food were also able to block pitavastatin-induced apoptosis, suggesting diet might influence the outcome of clinical trials; when nude mice were maintained on a diet lacking geranylgeraniol, oral pitavastatin caused regression of Ovcar-4 tumour xenografts; however, when the animal diet was supplemented with geranylgeraniol, pitavastatin failed to prevent tumour growth; this suggests that a diet containing geranylgeraniol can limit the anti-tumour activity of pitavastatin and diet should be controlled in clinical trials of statins.
Evidence strength assessment: In vitro cytotoxicity data on cancer cells are preliminary. The finding that GGOH may antagonize the anti-tumour effects of statins in animal models is a significant safety concern requiring attention. No human oncology trial data exist for GGOH as a cancer treatment.
5. Body Systems and Health Areas Associated with GGOH
- Musculoskeletal system: Prevention and reversal of statin-induced muscle damage; support of skeletal muscle protein synthesis and cell viability; bone microarchitecture and osteoblast/osteoclast function.
- Metabolic/energy system: Precursor to CoQ10 (mitochondrial energy production); glucose homeostasis and insulin sensitivity (animal data).
- Immune/inflammatory system: NF-κB pathway modulation; reduction of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, COX-2) in cell and animal models; potential role in autoinflammatory conditions involving mevalonate pathway disruption.
- Endocrine/reproductive system: Mevalonate pathway-dependent and independent regulation of steroidogenesis; precursor to testosterone in testicular cells (preclinical); registered clinical trial ongoing.
- Nervous system: Anti-neuroinflammatory activity in microglial cells; mitochondrial biogenesis support in diabetic neuropathy models.
- Gastrointestinal/microbiome: Modification of cecal microbiome composition in animal models; colon tight-junction integrity.
- Oral/dental (bone): Potential mitigation of bisphosphonate-related osteonecrosis of the jaw (preclinical and in vitro).
6. Dosage Forms and Dosages Reported in Studies
GGOH supplements are often formulated as softgels due to the compound's fat-soluble nature; doses used in human clinical studies have ranged from 150 mg to 300 mg per day, often administered in divided doses to enhance absorption; taking the supplement with meals may further improve its bioavailability.
In the registered testosterone clinical trial (NCT06747624), all participants receive 300 mg GG/daily (compared to 300 mg medium chain triglycerides/daily as placebo).
In a murine metabolic and bone study, HFD-fed male C57BL/6J mice received 800 mg GGOH/kg diet for 14 weeks.
In the combined GGOH and green tea polyphenols mouse study, the dose of geranylgeraniol was 400 mg GGOH/kg diet.
In a published dose-escalation randomized, double-blind, placebo-controlled human trial assessing blood safety and sex hormone profiles — referenced as Gheith et al., Nutraceuticals 3.4 (2023) — an 8-week, randomized, double-blind, placebo-controlled human trial investigated the systemic effects of escalating doses of annatto-derived GG, concluding that GG is highly safe, showing no adverse alterations in comprehensive metabolic panels, liver enzymes, blood chemistry, or hematology.
7. Safety Profile, Toxicological Evaluation, and Drug Interactions
7.1 Formal Toxicological Evaluation
GGOH is an isoprenoid compound found in annatto seeds and an intermediate of the mevalonate pathway; formal toxicological studies on its safety profile are not readily available. A formal toxicological evaluation was published in Regulatory Toxicology and Pharmacology (Preece et al., 2021, PMID 34144118).
No negative effects appeared at doses up to 725 mg per kilogram of body weight per day over 90 days (in the animal toxicological study).
Current studies indicate that GGOH is well-tolerated at tested dosages (150–300 mg/day), with no significant adverse changes observed in standard blood safety markers during short-term trials; however, long-term safety data is not yet fully established.
7.2 Human Safety Data
Geranylgeraniol has demonstrated an excellent safety profile in human trials; an 8-week, randomized, double-blind, placebo-controlled human trial investigated the systemic effects of escalating doses of annatto-derived GG; the study concluded that GG is highly safe, showing no adverse alterations in comprehensive metabolic panels, liver enzymes, blood chemistry, or hematology.
Animal studies have also shown that GG may help prevent statin-induced skeletal muscle fatigue without interfering with the statin's therapeutic ability to lower serum cholesterol or causing adverse effects on cardiovascular function.
7.3 Potential Drug Interactions — Statins
Geranylgeraniol, a cell-permeable analogue of GGPP, reversed all the cellular effects of mevastatin without affecting its ability to reduce cholesterol synthesis. This is a mechanistically important property: GGOH acts downstream of HMG-CoA reductase, meaning that supplemental GGOH can potentially rescue isoprenoid depletion without abolishing the cholesterol-lowering efficacy of statins.
However, an opposing interaction concern exists in oncology contexts:
When the animal diet was supplemented with geranylgeraniol, pitavastatin failed to prevent tumor growth; this suggests that a diet containing geranylgeraniol can limit the anti-tumour activity of pitavastatin, and diet should be controlled in clinical trials of statins. This potential for GGOH to antagonize anti-cancer statin effects is a source-documented concern for patients using statins as potential anti-cancer agents.
7.4 Potential Drug Interactions — Bisphosphonates
FOH and GGOH have been shown to block the effects of isoprenoid biosynthesis inhibitors such as fosmidomycin, bisphosphonates, or statins in several organisms. While this is precisely the mechanism proposed to be therapeutic in MRONJ, it also means that GGOH could theoretically reduce the desired anti-resorptive (bone-protective) actions of bisphosphonates if used concurrently in a systemic context. This has not been formally studied in humans.
7.5 Interactions — Anti-Platelet and Anti-Coagulant Agents
The registered sexual health clinical trial (NCT05258513) excludes participants using drugs that are anti-diabetic, anti-platelet, anti-coagulant, beta blockers, or used to treat erectile dysfunction. This reflects investigator caution about potential interactions with anticoagulants, possibly mediated through the vitamin K2 biosynthesis pathway, since GGOH is the direct side-chain precursor of MK-4 (vitamin K2). Vitamin K compounds can counteract the anticoagulant effects of warfarin-type medications; however, the clinical significance of this specific interaction with GGOH supplementation has not been formally studied.
7.6 Interaction — Anti-Malarial Drugs
In vitro studies have demonstrated that prenols like geranylgeraniol (GGOH) can temporarily circumvent the MEP pathway, rescuing malaria parasites from fosmidomycin effects; a parasitic prenol kinase (PolK) is responsible for converting GGOH into its active pyrophosphate form in the parasite; additionally, GGOH's human plasma concentration is sufficient to affect MEP inhibitors. This suggests that physiological or supplemental levels of GGOH may influence the efficacy of fosmidomycin-based anti-malarial therapies.
7.7 Skin, Eye, and Respiratory Irritation
GG can irritate the skin, eyes, and respiratory system if not handled correctly. This is primarily a handling and occupational safety consideration relevant to industrial or research contexts; clinical supplement use via oral softgel is unlikely to present this risk.
References
Go back